23:01 , Mar 21, 2019 |  BC Extra  |  Financial News

Qiming backs Abbisko in $42M series B

Abbisko raised a $42 million series B round led by new investor Qiming Venture Partners to advance its oncology compounds into the clinic and further expand its discovery pipeline. Abbisko Therapeutics Co. Ltd. (Shanghai, China)...
21:28 , Feb 9, 2018 |  BioCentury  |  Emerging Company Profile

Fast boat to China

Abbisko Therapeutics aims to be first-to-market for common cancer indications in China with small molecules against clinically validated targets that are more potent than competing agents in development outside the country. Abbisko is focusing first...